Research programme: protein target therapeutics - Celgene/FORMA Therapeutics

Drug Profile

Research programme: protein target therapeutics - Celgene/FORMA Therapeutics

Alternative Names: Epigenetic compounds - Celgene/FORMA Therapeutics; Epigenetic compounds - FORMA Therapeutics/Celgene

Latest Information Update: 12 Sep 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator FORMA Therapeutics
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Non-alcoholic steatohepatitis

Most Recent Events

  • 07 Sep 2016 Preclinical trials in Non-alcoholic steatohepatitis in USA (unspecified route)
  • 17 Jun 2015 Protein target therapeutics licensed to Celgene Corporation in European Union
  • 17 Jun 2015 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top